WHO 2026 Tuberculosis Treatment Guidelines: Module 4
The 2026 tuberculosis treatment guidelines from WHO refine drug-resistant TB care by stratifying pre-XDR-TB treatment according to disease severity and drug susceptibility. They carry forward every valid 2025 recommendation, integrate child and adolescent TB management, and add palliative care to the support package for the first time. GRADE is retained, and each recommendation is labeled new, updated, or unchanged.
What the 2026 update actually covers
On September 25, 2026, the guideline issuer published the second edition of its consolidated tuberculosis guidelines, Module 4 on Treatment and Care. The document gathers current advice on screening, preventive therapy, diagnosis, patient support, and the treatment of drug-susceptible TB (DS-TB) and drug-resistant TB (DR-TB) into a single reference.
The stated aims are practical: to offer updated evidence-based recommendations for DS-TB and DR-TB, including for children and adolescents, people living with HIV, and people co-infected with hepatitis C virus; to merge all still-valid advice into one file with clear new, updated, or unchanged labels; to help national plans align with the End TB Strategy by promoting shorter, safer, and more person-centered treatment; and to name the research gaps that remain.
The second edition keeps the GRADE method and, for the first time, places a palliative care recommendation inside the care and support chapter. For programs deciding what to revise, the new, updated, and unchanged labels are the useful part.
Who the tuberculosis treatment guidelines are written for
The document speaks to ministry policy makers and to managers of national tuberculosis programs (NTPs), who decide which regimens to fund and how to monitor them. It also addresses clinicians, nurses, and pharmacists who prescribe, administer, and dispense the medicines.
Technical partners, researchers, and community organizations are named as readers too, because uptake depends on people outside the formal health system. Since the same reference now carries child and adolescent recommendations, pediatric providers and family-focused services are part of the intended readership. The 2026 tuberculosis treatment guidelines therefore work as a single reference across several levels of the system.
At a glance: new, updated, and unchanged recommendations
Most of the drug-susceptible chapter is carried over. The substantive revision sits in the drug-resistant chapter. The table separates what is new, what was updated after longer follow-up, and what continues unchanged.
Area | Recommendation | Code | Status |
MDR/RR-TB | Six-month BPaLM preferred over 9-month or 18-month treatment for most patients | B1.1 | Updated |
Non-severe pulmonary pre-XDR-TB | Six-month BPaL rather than BPaLC | B1.1a | New |
Severe pulmonary pre-XDR-TB | Six-month BPaLC rather than BPaL | B1.1b | New |
MDR/RR-TB with or without fluoroquinolone resistance | Six-month BDLLfx/C | B1.2 | Updated |
Non-severe pre-XDR-TB | Six-month BDLC rather than 18-month or longer treatment | B1.2a | New |
Severe pre-XDR-TB | Do not use six-month BDLC; use a longer regimen | B1.2b | New |
Nine-month all-oral regimens | Retained with ranking and exclusions | B2.1 to B2.4 | Unchanged |
Longer regimens | Retained | B3.1 to B3.17 | Unchanged |
Hr-TB, monitoring, ART, surgery, HCV | Retained | B4 to B8 | Unchanged |
Care and support | Retained | C1 to C3 | Unchanged |
Palliative care assessment and intervention | Integrate for pulmonary MDR/RR-TB | C4.1 | New |
Drug-susceptible TB chapter | Child and adolescent material integrated | A1 to A5 | Unchanged |
Everything else in the 2025 first edition remains valid without change.
Drug-susceptible TB: four-month regimens and child adolescent integration
Chapter 1 folds in the material on child and adolescent tuberculosis management. The regimen abbreviations below use the standard shorthand: H for isoniazid, R for rifampicin, Z for pyrazinamide, and E for ethambutol.
Population | Regimen | Code | Strength | Status |
12 years and older with drug-susceptible pulmonary TB | Four-month isoniazid, rifapentine, moxifloxacin, and pyrazinamide | A2.1 | Conditional | Maintained |
3 months to 16 years with non-severe TB | Four-month 2HRZ(E)/2HR | A2.2 | Strong | Maintained |
Children with pulmonary TB or peripheral lymphadenitis | 2HRZ/4HR | A1.6a | Not stated | Unchanged |
Children and adolescents with severe pulmonary disease | 2HRZE/4HR | A1.6b | Not stated | Unchanged |
Infants aged 0 to 3 months with suspected or confirmed pulmonary TB | Six-month 2HRZ(E)/4HR | A1.6c | Not stated | Unchanged |
Children with TB meningitis or osteoarticular TB | 2HRZE/10HR, 12 months total | A5.1 | Not stated | Unchanged |
Children and adolescents with TB meningitis and no MDR/RR-TB evidence | Six-month 6HRZEtO as an alternative | A5.2 | Not stated | Unchanged |
HIV co-infection | Daily therapy at least as long as for HIV-negative patients, with ART within 2 weeks | A3.1, A3.2 | Not stated | Unchanged |
Two four-month options are central to this chapter. For people aged 12 years and older with drug-susceptible pulmonary TB, the combination of isoniazid, rifapentine, moxifloxacin, and pyrazinamide carries a conditional recommendation. For children aged 3 months to 16 years with non-severe disease, the 2HRZ(E)/2HR schedule carries a strong recommendation. Infants from birth to 3 months receive a six-month course, and dosing in this group may need adjustment by an experienced pediatric TB clinician.
For TB meningitis and osteoarticular disease, the total duration is 12 months on 2HRZE/10HR. In selected children and adolescents with TB meningitis and no suspicion or evidence of MDR/RR-TB, the six-month 6HRZEtO intensive regimen remains an alternative. For people living with HIV, daily TB therapy should run for at least as long as it would in a person without HIV, and antiretroviral therapy should start as early as possible within 2 weeks of beginning TB treatment.
How the 2026 tuberculosis treatment guidelines stratify drug-resistant TB
Chapter 2 is where the update concentrates. It draws on extended follow-up from three studies, BEAT Tuberculosis, endTB-Q, and TB-PRACTECAL, to make the treatment of pre-extensively drug-resistant TB (pre-XDR-TB) more granular. The update splits pre-XDR-TB by disease severity and by fluoroquinolone susceptibility, then matches the regimen to that split.
Fluoroquinolone drug susceptibility testing is strongly encouraged, yet a pending result must not hold up the start of therapy. A patient begins on a regimen that covers both possibilities, and the result is used afterward to decide which drug to keep, which to replace, and whether a longer course is needed.
BPaLM, BPaL, and BPaLC by disease severity
The first family uses bedaquiline, pretomanid, and linezolid, with moxifloxacin or clofazimine added according to the scenario. BPaLM means bedaquiline, pretomanid, linezolid, and moxifloxacin. Removing moxifloxacin gives BPaL, and replacing it with clofazimine gives BPaLC.
Scenario | Regimen | Full drug names | Recommendation | Code |
Most MDR/RR-TB | BPaLM, six months | Bedaquiline, pretomanid, linezolid, moxifloxacin | Use instead of a 9-month or 18-month regimen | B1.1, updated |
Non-severe pulmonary pre-XDR-TB | BPaL, six months | Bedaquiline, pretomanid, linezolid | Prefer over BPaLC | B1.1a, new |
Severe pulmonary pre-XDR-TB | BPaLC, six months | Bedaquiline, pretomanid, linezolid, clofazimine | Prefer over BPaL | B1.1b, new |
Fluoroquinolone resistance unknown | Start BPaLM, then adjust | As above | Do not delay treatment | Guidance |
Fluoroquinolone susceptibility confirmed | Continue BPaLM | As above | Keep moxifloxacin | Guidance |
Pre-XDR-TB with severe disease and fluoroquinolone resistance | Switch moxifloxacin to clofazimine, giving BPaLC | As above | Use BPaLC | Guidance |
Pre-XDR-TB with non-severe disease | Continue BPaLM or switch to BPaL | As above | Either is acceptable | Guidance |
Severe disease means cavitation on chest imaging with a sputum bacterial load of 1+ or above, or, without a cavity, a load of 2+ or above or a molecular test equivalent. The distinction decides the regimen: severe disease uses clofazimine in place of moxifloxacin.
BDLLfxC and BDLC by disease severity
The second family pairs bedaquiline and delamanid with linezolid. BDLLfxC means bedaquiline, delamanid, linezolid at 600 mg, levofloxacin, and clofazimine. Withholding clofazimine gives BDLLfx, and withholding levofloxacin gives BDLC, which is bedaquiline, delamanid, and linezolid.
Scenario | Regimen | Full drug names | Recommendation | Code |
MDR/RR-TB with or without fluoroquinolone resistance | BDLLfx/C, six months | Bedaquiline, delamanid, linezolid 600 mg, levofloxacin, with or without clofazimine | Use | B1.2, updated |
Non-severe pulmonary pre-XDR-TB | BDLC, six months | Bedaquiline, delamanid, linezolid | Prefer over 18-month or longer treatment | B1.2a, new |
Severe pulmonary pre-XDR-TB | Avoid six-month BDLC | Not applicable | Use a longer regimen instead | B1.2b, new |
Fluoroquinolone resistance unknown | Start BDLLfxC | As above | Do not delay treatment | Guidance |
Fluoroquinolone susceptibility confirmed | Stop clofazimine, continue BDLLfx | As above | Keep levofloxacin | Guidance |
Non-severe pulmonary pre-XDR-TB | Stop levofloxacin, continue BDLC | As above | Use BDLC | Guidance |
Severe pulmonary pre-XDR-TB | Do not use BDLC | Consider BPaLC or an individualized longer regimen | Avoid six-month BDLC | Guidance |
This set applies to people of all ages, including children and adolescents, and to people living with HIV, pregnant women, and women who are lactating. It excludes central nervous system disease, osteoarticular TB, and multi-organ disseminated extrapulmonary TB. The linezolid dose stated in the recommendation is 600 mg.
Nine-month all-oral options and what is not recommended
The nine-month all-oral family is retained from the first edition. The abbreviations expand as follows: BLMZ is bedaquiline, linezolid, moxifloxacin, and pyrazinamide. BLLfxCZ is bedaquiline, linezolid, levofloxacin, clofazimine, and pyrazinamide. BDLLfxZ is bedaquiline, delamanid, linezolid, levofloxacin, and pyrazinamide. DCLLfxZ is delamanid, clofazimine, levofloxacin, and pyrazinamide. DCMZ is delamanid, clofazimine, moxifloxacin, and pyrazinamide.
Recommendation | Content | Code | Status |
Use a nine-month all-oral regimen rather than an 18-month one when fluoroquinolone resistance has been excluded | Nine months instead of 18 | B2.1 | Unchanged |
Rank the three nine-month options | BLMZ preferred over BLLfxCZ, which is preferred over BDLLfxZ | B2.2 | Unchanged |
Do not use two nine-month options in fluoroquinolone-susceptible MDR/RR-TB | DCLLfxZ and DCMZ are not recommended | B2.3 | Unchanged |
Use a bedaquiline-containing all-oral regimen in children under 6 years | Bedaquiline-based all-oral treatment | B2.4 | Unchanged |
B2.2 sets a preference order among the three nine-month options. B2.3 rules out two combinations entirely in fluoroquinolone-susceptible disease.
Longer regimens, Hr-TB, monitoring, and surgery stay the same
Several blocks of Chapter 2 in the tuberculosis treatment guidelines were left intact. Recommendations B3.1 through B3.17 on longer regimens and B4.1 and B4.2 on rifampicin-susceptible, isoniazid-resistant TB (Hr-TB) all stay as they were. The Hr-TB advice is rifampicin, ethambutol, pyrazinamide, and levofloxacin for 6 months, with no streptomycin or other injectable agent added.
Monitoring (B5.1), antiretroviral therapy (B6.1), surgery (B7.1), and hepatitis C co-administration (B8.1) were left as they were.
Palliative care enters tuberculosis care for the first time
Chapter 3 covers care and support. C1 through C3 stay as they were. C4.1 is new and applies to people with pulmonary MDR/RR-TB.
Area | Recommendation | Code | Status |
Health education and counseling | Retained | C1 | Unchanged |
Adherence support package | Retained | C2 | Unchanged |
Community and home support, video-supported therapy, decentralized care for MDR-TB, and family-centered care for children and adolescents | Retained | C3 | Unchanged |
Palliative care assessment and intervention by trained providers for pulmonary MDR/RR-TB | Integrate alongside effective treatment | C4.1 | New |
Selected patients with drug-susceptible TB after a needs assessment | The same approach may apply | C4.1 | New |
C4.1 is conditional and rests on moderate-certainty evidence from a randomized trial in Uganda. A nurse-led palliative care intervention in that trial improved symptom relief, quality of life, psychological distress, and adherence to TB medication. The guideline notes that the intervention can also extend to selected patients with drug-susceptible TB once a needs assessment identifies a need.
How the evidence was graded
The GRADE framework remains the method behind the recommendations. Certainty is rated as high, moderate, low, or very low, and recommendation strength is rated as strong or conditional. Most of the new and updated recommendations are conditional and rest on very low to moderate certainty. The recurring limits are small sample sizes, non-blinded study designs, and indirectness.
The guideline pairs the grades with concrete instructions. Strengthen drug susceptibility testing capacity for fluoroquinolones, bedaquiline, and linezolid. Treatment choice should weigh disease severity, susceptibility results, prior drug exposure, comorbidities, and patient preference. Patient support, adverse event monitoring, and attention to drug interactions are part of the same package. Countries are asked to write the new recommendations into their national tuberculosis plans and into monitoring and evaluation frameworks.
What changed and what stayed the same
The comparison below shows where national guidance needs revision.
Domain | Second edition, 2026 | Compared with the 2025 first edition |
Pre-XDR-TB treatment | Split by severity and fluoroquinolone susceptibility | New stratification |
BPaLM for most MDR/RR-TB | Six months preferred | Updated |
BDLLfx/C | Six months with or without fluoroquinolone resistance | Updated |
Palliative care | Formally included in care and support | New |
Drug-susceptible TB chapter | Child and adolescent material folded in | Recommendations unchanged |
Nine-month, longer, Hr-TB, monitoring, ART, surgery, and HCV sections | Retained | Unchanged |
Care and support C1 to C3 | Retained | Unchanged |
Other than the items marked new or updated, all 2025 recommendations remain valid: the entire Chapter 1 set on DS-TB treatment; the nine-month all-oral and longer regimens in Chapter 2; Hr-TB, monitoring, ART, surgery, and HCV co-administration; and C1 through C3 in Chapter 3.
Why the shorter regimen is not always the right one
Two findings cut against using the shortest course everywhere. The six-month BDLC regimen is specifically not advised for severe pulmonary pre-XDR-TB, even though it is preferred for non-severe disease, because severity changes which regimen fits.
Second, a missing fluoroquinolone resistance result is not a reason to wait. Therapy starts on BPaLM or BDLLfxC, and the result is used afterward to decide whether to keep moxifloxacin or levofloxacin, to swap in clofazimine, or to move to a longer regimen. The 2026 tuberculosis treatment guidelines spell out that revision step.
Practical steps for national programs and clinicians
- Set up or expand drug susceptibility testing for fluoroquinolones, bedaquiline, and linezolid.
- Classify pulmonary pre-XDR-TB by cavitation and sputum bacterial load before selecting a regimen.
- Start BPaLM or BDLLfxC while fluoroquinolone results are pending, then adjust when they arrive.
- Avoid six-month BDLC in severe pre-XDR-TB and in extrapulmonary disease outside the permitted sites.
- Add palliative care assessment to pulmonary MDR/RR-TB services using trained providers.
- Provide adherence support, monitor adverse events, and check for drug interactions.
- Write the new and updated labels into national plans and into monitoring and evaluation frameworks.
Limitations of the evidence and this summary
This summary of the tuberculosis treatment guidelines reflects the published second edition and the evidence cited in it. Several new and updated recommendations carry only conditional strength and very low to moderate certainty, so the details may shift as longer follow-up accumulates. The severity threshold depends on imaging and sputum grading, both of which vary in routine practice.
The evidence base does not cover every extrapulmonary site, and the palliative care trial was conducted in one country. The text here reproduces guideline codes and drug names but does not replace the full document or local clinical judgment.
Bottom line
The second edition of Module 4 keeps the 2025 foundation intact and adds a more precise frame for drug-resistant disease. For most MDR/RR-TB, six-month BPaLM remains the default. For pre-XDR-TB, non-severe disease goes to BPaL or BDLC, while severe disease goes to BPaLC or a longer regimen, and six-month BDLC is avoided. Four-month options for drug-susceptible TB stay in place, and palliative care joins the support package. Programs and clinicians should read the new and updated labels closely, because those are the places where policy actually moved. The tuberculosis treatment guidelines now ask for severity-based choices backed by susceptibility testing.
FAQ
What are the 2026 tuberculosis treatment guidelines for MDR-TB?
They keep the 2025 recommendations and add a more stratified approach to drug-resistant disease. For most people with MDR/RR-TB, a six-month BPaLM regimen is preferred over nine-month or 18-month treatment. For pre-XDR-TB, the regimen depends on disease severity: non-severe pulmonary disease uses BPaL, while severe pulmonary disease uses BPaLC. A second family, BDLLfx/C, offers another six-month option with or without fluoroquinolone resistance. Fluoroquinolone testing is encouraged but must not delay treatment. Palliative care is included for the first time.
How do I choose between BPaLM and BPaL for pre-XDR-TB?
BPaLM contains moxifloxacin, so it is the starting point when fluoroquinolone resistance is unknown or when susceptibility is confirmed. If testing shows the organism is susceptible, BPaLM is continued. If resistance is present and the disease is severe, moxifloxacin is replaced with clofazimine to give BPaLC. If resistance is present and the disease is non-severe, treatment continues on BPaLM or switches to BPaL. The choice therefore rests on the susceptibility result and on how severe the lung disease is.
How do I define severe pulmonary pre-XDR-TB?
Severe disease is defined by cavitation on chest imaging together with a high sputum bacterial load. The bacterial load threshold is 1+ or above when a cavity is present. When there is no cavity, the threshold rises to 2+ or above, or a molecular test equivalent. This definition decides which regimen is appropriate: severe disease calls for BPaLC or a longer regimen, while non-severe disease can use BPaL or BDLC. Imaging and sputum grading should be done before treatment starts whenever possible.
When should I use BPaLC instead of BPaL?
BPaLC adds clofazimine to bedaquiline, pretomanid, and linezolid. It is recommended for people with severe pulmonary pre-XDR-TB, where it is preferred over BPaL. It is also the option named when fluoroquinolone resistance is confirmed in severe disease, replacing moxifloxacin with clofazimine. For non-severe pulmonary pre-XDR-TB, BPaL is preferred and BPaLC is not needed. The distinction is severity driven, so assess cavitation and sputum bacterial load before deciding.
What does BDLLfxC stand for and when is it used?
BDLLfxC is a six-month all-oral regimen of bedaquiline, delamanid, linezolid at 600 mg, levofloxacin, and clofazimine. It is recommended for people with MDR/RR-TB with or without fluoroquinolone resistance. If fluoroquinolone resistance is unknown, treatment starts on BDLLfxC. If susceptibility is confirmed, clofazimine is stopped and BDLLfx is continued. It applies to all ages, including children, and to people living with HIV, pregnant women, and lactating women, but not to central nervous system, osteoarticular, or multi-organ disseminated disease.
Why is BDLC not recommended for severe pre-XDR-TB?
BDLC is a six-month combination of bedaquiline, delamanid, and linezolid. It is preferred for non-severe pulmonary pre-XDR-TB, where it replaces an 18-month or longer course. For severe pulmonary pre-XDR-TB, the recommendation explicitly says not to use the six-month BDLC regimen. Instead, a longer regimen is advised, and BPaLC or an individualized longer regimen is considered. The reason is that the shorter option was not supported for the severe group in the evidence reviewed.
Which nine-month all-oral regimen is preferred?
When fluoroquinolone resistance has been excluded, a nine-month all-oral regimen is preferred over an 18-month one. Among the options, BLMZ, which is bedaquiline, linezolid, moxifloxacin, and pyrazinamide, ranks first. BLLfxCZ, containing levofloxacin and clofazimine, ranks second, and BDLLfxZ ranks third. Two other combinations, DCLLfxZ and DCMZ, are not recommended for fluoroquinolone-susceptible MDR/RR-TB. Children under six years may use a bedaquiline-containing all-oral regimen.
Are the four-month regimens still an option for drug-susceptible TB?
Yes. For people aged 12 years and older with drug-susceptible pulmonary TB, a four-month regimen of isoniazid, rifapentine, moxifloxacin, and pyrazinamide remains an option with a conditional recommendation. For children aged 3 months to 16 years with non-severe TB, a four-month 2HRZ(E)/2HR schedule is strongly recommended. Younger infants use a six-month course, and TB meningitis or osteoarticular disease still requires 12 months on 2HRZE/10HR. These recommendations were carried over unchanged.
When should ART start in HIV co-infected patients?
Antiretroviral therapy should start as early as possible, and within 2 weeks of beginning TB treatment. People living with HIV should receive daily TB therapy for at least as long as patients who are HIV negative. This recommendation was not changed in the second edition. The timing matters because the two infections interact and because delaying antiretroviral therapy increases risk. Programs should make sure the two services are linked so the 2-week target is realistic in practice.
What does the new palliative care recommendation involve?
The new C4.1 recommendation asks trained providers to integrate a palliative care assessment and intervention for people with pulmonary MDR/RR-TB, alongside effective treatment. It is conditional and based on moderate-certainty evidence from a randomized trial in Uganda. In that trial, a nurse-led intervention improved symptom relief, quality of life, psychological distress, and adherence to TB medicine. The approach can also apply to selected patients with drug-susceptible TB after a needs assessment shows a need.
How certain is the evidence behind these new recommendations?
Most of the new and updated recommendations are conditional, and the certainty of evidence runs from very low to moderate. The main limitations are small sample sizes, non-blinded study designs, and indirectness. Only the palliative care recommendation is described as resting on moderate-certainty evidence. GRADE was retained as the method, so each recommendation is labeled strong or conditional and the certainty is stated. Readers should treat the details as likely to change as longer follow-up becomes available.
Which recommendations did not change in the second edition?
All other 2025 recommendations remain valid unchanged. That includes the full Chapter 1 set on drug-susceptible TB, the nine-month all-oral regimens, the longer regimens, Hr-TB, monitoring, ART, surgery, and HCV co-administration in Chapter 2, and the C1 through C3 care and support recommendations in Chapter 3. The drug-susceptible chapter now folds in child and adolescent material, but the recommendations themselves were not altered. Only the B1 items and C4.1 carry new or updated status.